NASDAQ: PTGX · Biotechnology

Protagonist Therapeutics (PTGX) fair value: undervalued or overvalued?

As of 16 Nov 2026, Faircurve's model values Protagonist Therapeutics (PTGX) at $104.97 a share. The stock last closed at $124.67, which puts the model's fair value 15.8% below the price. On the model's bands that reads as Overvalued.

Revalued . Price is the close of 17 Nov 2026. Protagonist Therapeutics, Inc.

The report adds the live price, the chart against the range the options market prices and the next earnings date. No account needed.

Model fair value$104.97midpoint of 2,000 simulations
Last close$124.67NASDAQ: PTGX
Gap to fair value-15.8%fair value against price
Model verdictOvervaluedevidence grade: Medium

This week, in three parts

What happenedThe run of 16 Nov 2026 moved the fair value from $106.93 to $104.97 (-1.8%). The move is not broken down.

What the model makes of itThe price of $124.67 is 15.8% above it: Overvalued, on a medium evidence grade.

What's nextNext report on 24 Feb 2027. Options prices imply a move of about 12% either way over the next month. On the model's Scorecard Leaders list since 2 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give PTGX?

The calibrated range for PTGX over 63 trading days is $108.66 to $144.03. It sits around the last close, and its width comes from the volatility that PTGX's own options imply (42% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $69.20 to $156.88. In 33% of the simulations the fair value came out above the price the model ran on.

$44.32$321.85
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $104.97. Dashed line: the last close, $124.67.

Faircurve Insights · 16 Nov 2026

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. It sits in the healthcare sector, under biotechnology.

Faircurve's model put the fair value at $104.97 a share on 16 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $106.93, so the fair value moved -1.8%. The model's reason: the move is not broken down. The calibrated range over 63 trading days is $114.66 to $150.56. It is built around the price from the volatility the stock's own options imply, calibrated weekly against realised prices. Ranges built this way held the price 60% of the time at this horizon, across 8,038 past valuations refreshed on 14 Nov 2026. The evidence grade is Medium. The grade reflects input completeness, peer count and agreement, and range width. It does not test whether the fair value is right.

Protagonist scores 55 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Profitability scores 100, with ROIC of 53.0% against a peer median of -36.3%. Stability scores 0, with 5y EBITDA margin downside volatility of 131.5 pts against a peer median of 32.7 pts. The model compares it with TG Therapeutics, Inc. (TGTX), BioMarin Pharmaceutical Inc. (BMRN) and Bio-Techne Corporation (TECH).

Written from the figures on this page for the 16 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does PTGX report earnings, and how has the stock reacted?

Protagonist Therapeutics's next earnings report is scheduled for 24 Feb 2027. Companies can move their dates.

Options prices on 17 Nov 2026 imply a move of about 9.5% in either direction through the nearest expiry, about 30 days out. That is the size the market is pricing, not a direction. PTGX's 30 day implied volatility works out to about 12.0% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across PTGX's last 8 reports, ignoring direction, was 5.0%.

0%10%20%30%28.8%2.9%7 Nov '2431.0%6.5%21 Feb '25no quote5.5%6 Aug '2510.8%2.1%6 Nov '2511.1%1.1%25 Feb '2618.2%4.5%5 May '2614.5%7.6%5 Aug '2610.5%7.9%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in PTGX

5%10%15%20%25%5 Nov '26 report5 Aug '26 report5 May '26 report25 Feb '26 report12% at 17 Nov '2624 Nov '2517 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 11% on 24 Nov 2025, reached 20% on 23 Jul 2026 and reads 12% on 17 Nov 2026. The marks are report dates.

How does PTGX score on business quality?

Protagonist Therapeutics's overall quality score is 55 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.10053.0%ROIC-36.3%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).170.32xFCF / net income
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.23-89.4%Revenue growth, trailing66.6%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.750.1%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.100-1.39xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.0131.5 ptsEBITDA margin downside volatility, 5y32.7 pts

How does PTGX compare with similar companies?

The companies in biotechnology closest to Protagonist Therapeutics in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
KRYS Krystal Biotech, Inc.$298.55$352.42+18.0%Low evidence grade
CYTK Cytokinetics, Incorporated$51.65$63.03+22.0%Low evidence grade
TGTX TG Therapeutics, Inc.$62.71$75.36+20.2%Undervalued
ARWR Arrowhead Pharmaceuticals, Inc.$42.99$53.67+24.8%Low evidence grade
BMRN BioMarin Pharmaceutical Inc.$58.51$69.09+18.1%Undervalued
HALO Halozyme Therapeutics, Inc.$95.97$111.93+16.6%Low evidence grade
TECH Bio-Techne Corporation$72.63$65.76-9.5%Fairly valued
LGND Ligand Pharmaceuticals Incorporated$293.81$282.99-3.7%Low evidence grade

What the comparable companies' multiples alone would give for PTGX, the peer-implied price, is $208.38 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

Protagonist Therapeutics at a glance

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies.

Market value
$8.5B
Sector
Healthcare
Industry
Biotechnology
Beta to the US market
0.87
First valued by Faircurve
11 Jul 2026

At the close of 17 Nov 2026, 62.4% of the 1,083 graded US stocks the model covers traded below the model's fair value. PTGX was not among them.

How the fair value is worked out: the model prices Protagonist Therapeutics on the price of comparable companies relative to their profits (a peer multiple), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for PTGX was $106.93. As of 16 Nov 2026 it is $104.97, a change of -1.8%. The move is not broken down. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Protagonist Therapeutics's valuation

Is Protagonist Therapeutics stock undervalued or overvalued?

On Faircurve's model, PTGX reads as Overvalued as of 16 Nov 2026. The model's fair value is $104.97 a share against a last close of $124.67, a gap of -15.8%.

What is PTGX's fair value?

$104.97 a share as of 16 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $69.20 to $156.88.

What price range does the model give PTGX?

$108.66 to $144.03 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Protagonist Therapeutics report earnings next?

The next report is scheduled for 24 Feb 2027. Companies can move their dates.

How much has PTGX moved on past earnings reports?

Across its last 8 reports the median two session move was 5.0%, ignoring direction. The largest was -7.9% around the report of 5 Nov 2026.

How confident is the model in this valuation?

The model's evidence grade for PTGX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on PTGX

The model has an idea open on PTGX under Scorecard Leaders since 2 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on PTGX with their outcomes. A free account is enough.

Keep reading